Literature DB >> 10519585

Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey.

M H Reinke1, C Canakis, D Husain, N Michaud, T J Flotte, E S Gragoudas, J W Miller.   

Abstract

OBJECTIVE: This study evaluated the effect of repeated photodynamic therapy (PDT) applications on normal primate retina and choroid using an intravenous infusion of liposomal benzoporphyrin derivative (verteporfin).
DESIGN: This was an experimental study in a primate model. ANIMALS/CONTROLS: Six cynomolgus monkeys were used as experimental subjects and one monkey was used as a control subject. INTERVENTION: Three consecutive PDT treatments at 2-week intervals were applied over the center of the fovea or the optic nerve of each eye. Verteporfin was delivered by intravenous infusion at a dose of 6 mg/m2, 12 mg/m2, or 18 mg/m2. Laser irradiation was then applied using a diode laser (689 nm) with light doses and spot sizes kept constant. MAIN OUTCOME MEASURES: Findings were documented by fundus photography, fluorescein angiography, and light and electron microscopy.
RESULTS: A cumulative dose response was seen angiographically and histologically with more severe damage to the retina and choroid noted at higher dye doses. Photodynamic therapy applied to the macula using the 6-mg/m2 verteporfin dose showed recovery of choriocapillaris, with mild retinal pigment epithelium and outer photoreceptor damage at 6 weeks. At this dose, the optic nerve showed few focal sites of axon atrophy and capillary loss. Treatments over the macula using the 12-mg/m2 and 18-mg/m2 doses led to chronic absence of choriocapillaris and photoreceptors at 6 weeks. One of two optic nerves became atrophic after PDT applications using dye doses of 12 mg/m2, and both optic nerves became atrophic in the 18-mg/m2 dye dose group.
CONCLUSION: Limited damage to the retina, choroid, and optic nerve was present in primates treated with multiple PDT sessions using 6 mg/m2 verteporfin with light doses and the timing of irradiation kept constant. However, PDT using higher dye doses of 12 mg/m2 and 18 mg/m2 led to significant chronic damage to the normal retina, choroid, and optic nerve.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519585     DOI: 10.1016/S0161-6420(99)90401-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  27 in total

Review 1.  Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.

Authors:  G Soubrane; N M Bressler
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Magnification-corrected photodynamic therapy.

Authors:  Siamak Ansari-Shahrezaei; Erdem Ergun; Robert Chong; Adnan Tufail; Andreas Wedrich; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-06       Impact factor: 3.117

3.  Early OCT changes of neuroretinal foveal thickness after first versus repeated PDT in AMD.

Authors:  Gennady Landa; Amir Bukelman; Haya Katz; Ayala Pollack
Journal:  Int Ophthalmol       Date:  2007-12-20       Impact factor: 2.031

4.  Influence of photodynamic therapy for age related macular degeneration upon subjective vision related quality of life.

Authors:  Alex W Hewitt; V Swetha Jeganathan; Juanita E Kidd; Konrad Pesudovs; Nitin Verma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

5.  Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.

Authors:  Vladimir Sheptulin; Konstantine Purtskhvanidze; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-10       Impact factor: 3.117

6.  Association between photoreceptor integrity and visual outcome in diabetic macular edema.

Authors:  Hyun Jin Shin; Seung Hyen Lee; Hyewon Chung; Hyung Chan Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-27       Impact factor: 3.117

Review 7.  Age-related macular degeneration: epidemiology and optimal treatment.

Authors:  Morten la Cour; Jens Folke Kiilgaard; Mogens Holst Nissen
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).

Authors:  Joan W Miller
Journal:  Trans Am Ophthalmol Soc       Date:  2008

9.  Prognostic factors related to photodynamic therapy for central serous chorioretinopathy.

Authors:  Jun Woong Moon; Hyeong Gon Yu; Tae Wan Kim; Hyung Chan Kim; Hum Chung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-07       Impact factor: 3.117

10.  The chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.

Authors:  Lan-Hsin Chuang; Yih-Shiou Hwang; Nan-Kai Wang; Yen-Po Chen; Laura Liu; Ling Yeung; Kuan-Jen Chen; Tun-Lu Chen; Wei-Chi Wu; Chi-Chun Lai
Journal:  J Ocul Pharmacol Ther       Date:  2014-06-20       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.